Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to tackle tough bone cancer

NCT ID NCT07620431

Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether giving radiation and chemotherapy together before surgery can help control high-risk Ewing sarcoma, a type of bone cancer. Researchers will follow 55 patients to see how well the treatment works and how safe it is. The goal is to improve local tumor control and survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiation therapy and chemotherapy before surgery
What this could lead to
If successful, this approach could improve local tumor control and survival for patients with high-risk Ewing sarcoma.
What could go wrong
This is a small, single-center observational study, not a randomized trial. Results may not apply broadly, and there are risks of wound complications and infections from the combined treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 55 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Initial treated ewing sarcoma patients in PKUPH and later would recieve definitivesurgery in PKUPH with complete clinical materials.

Ages

12 months and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The subject or their legal representative signs the written informed consent prior to enrollment. 2. Age \<= 55 years old. 3. Histologically confirmed Ewing sarcoma, with FET family (including EWSR1 or FUS) gene rearrangement confirmed by FISH or NGS. Clear FET-non ETS fusion cases are excluded. 4. Deemed difficult to achieve a satisfactory surgical margin by 2 or more senior musculoskeletal oncologists. 5. ECOG Performance Status: 0-1. 6. Expected life expectancy \>= 3 months. 7. Women of childbearing potential must have a negative pregnancy test within 1 week prior to enrollment and agree to use contraception; male subjects must agree to use contraception or have undergone surgical sterilization during the study. Exclusion Criteria: 1. No opportunity for surgical resection after neoadjuvant chemotherapy. 2. Extensive metastasis with no indication for local surgical resection. 3. Uncontrolled concurrent medical conditions. 4. Prior radiotherapy to the surgical site during front-line treatment. 5. History of other malignant tumors within the past 5 years. 6. Inability to cooperate with preoperative neoadjuvant radiotherapy (e.g., due to psychiatric factors). 7. Any condition that, in the investigator's judgment, might harm the patient or prevent compliance with study requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bone cancer bone neoplasm Ewing sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone neoplasms Ewing sarcoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University People's Hospital, Beijing, Beijing 100044

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.